Skip to main content
  • COAPT: Mortality or Rehospitalization Remains Significantly Lower for MitraClip over Optimal Medical Therapy at 3 Years

    SAN FRANCISCO – MitraClip’s lower rates of mortality and heart failure rehospitalization over optimal medical therapy remained significant at 3 years, according to the latest COAPT trial results presented Saturday at Transcatheter Cardiovascular Therapeutics 2019.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details